News and Trends 31 Oct 2016 Shooting for the Moon: German Biotech Acquired for a Record €1.3B Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops… October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Dec 2024 10 biotech companies to watch in 2025 …the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer. This approval makes Jazz’s drug the first dual HER2-targeted bispecific antibody specifically indicated for patients with… December 16, 2024 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 15 May 2024 Drugs for IgA nephropathy on the rise in the clinic …the kidneys against placebo in a phase 3 trial. The study is set to end next year. Moreover, Boston-based Alexion Pharmaceuticals’ monoclonal antibody ALXN1210, also known as ravulizumab is currently… May 15, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2019 Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies… January 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2022 €80M Series B Establishes European Champion in Radiopharmaceuticals …cancer-seeking component is a fragment of an antibody found in animals from the camelid family, which includes llamas and camels. These antibody fragments bind to their targets as strongly as… March 17, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2025 Serial acquirer Concentra Biosciences on a buyout spree in 2025 …been around for 30 years – known as Palingen until a rebrand in 2010 – the antibody developer had started out to design IgM therapies. However, when Sanofi dumped IGM… July 15, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Interview 2 Sep 2020 An Alzheimer’s Vaccine Challenged the Consensus for 25 Years …proteins interact with each other, forming aggregates. The team at Axon was able to identify it by developing an antibody that blocked the interaction between tau proteins by targeting that… September 2, 2020 - 8 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 May 2023 5 cancers that immunotherapy can cure …for multiple myeloma.The first three approved immunotherapies for multiple myeloma were antibody-based immunotherapies, all approved for subsets of patients with advanced multiple myeloma: daratumumab (Darzalex) – a monoclonal antibody targeting… May 9, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links …a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the IL-17 receptor, is part… July 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 2 Jan 2017 The Story behind one of the Most Successful Danish Biotech Entrepreneurs …became co-founders of Symphogen. I was in my 30s and we believed everything was possible, including building the next big antibody company; an idea inspired by Genmab, now a €10Bn… January 2, 2017 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 Understand your Biologics: De-Risking the Biotech Pipeline …of the top-selling drugs worldwide are antibodies and recombinant proteins, and new technologies such as Antibody-Drug Conjugates (ADCs) are on track to revolutionize the extremely challenging oncology field. However, since… June 14, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Startup Scout 22 Sep 2022 Cartography Biosciences unearths cancer immunotherapy targets …as partnered programs. Parker said that there are many potential partners out there developing donor cell immunotherapies, engineered antibody drugs and antibody-drug conjugates. “All of them need new targets,” he… September 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email